中期胸腺和激活调节趋化因子与氟代脱氧葡萄糖正电子发射断层扫描在经典型霍奇金淋巴瘤反应评估中的比较。
Interim thymus and activation regulated chemokine versus interim F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation.
机构信息
Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
出版信息
Br J Haematol. 2020 Jul;190(1):40-44. doi: 10.1111/bjh.16514. Epub 2020 Feb 27.
Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86% for iTARC and 85% for iPET. Serum iTARC levels more accurately reflect treatment response with a higher PPV compared to iPET.
血清胸腺和激活调节趋化因子（TARC）水平反映经典霍奇金淋巴瘤（cHL）的疾病活动情况，并与治疗反应相对应。我们比较了 95 例 cHL 患者治疗中期的 TARC（iTARC）与中期 F-氟脱氧葡萄糖正电子发射断层扫描（iPET）成像，以预测改良无进展生存期（mPFS）。9 例患者 iTARC 水平较高，17 例患者 iPET 阳性。与 iPET 相比，iTARC 对 5 年 mPFS 事件的阳性预测值（PPV）为 88%，而 iPET 为 47%。阴性预测值方面，iTARC 和 iPET 分别为 86%和 85%，两者相当。与 iPET 相比，血清 iTARC 水平更能准确反映治疗反应，其阳性预测值更高。
Zotero 插件